68 related articles for article (PubMed ID: 30636773)
1. Circulating tumour cells and their association with bone metastases in patients with neuroendocrine tumours.
Rizzo FM; Vesely C; Childs A; Marafioti T; Khan MS; Mandair D; Cives M; Ensell L; Lowe H; Akarca AU; Luong T; Caplin M; Toumpanakis C; Krell D; Thirlwell C; Silvestris F; Hartley JA; Meyer T
Br J Cancer; 2019 Feb; 120(3):294-300. PubMed ID: 30636773
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients.
Roumeliotou A; Strati A; Chamchougia F; Xagara A; Tserpeli V; Smilkou S; Lagopodi E; Christopoulou A; Kontopodis E; Drositis I; Androulakis N; Georgoulias V; Koinis F; Kotsakis A; Lianidou E; Kallergi G
Cells; 2024 May; 13(9):. PubMed ID: 38727318
[TBL] [Abstract][Full Text] [Related]
3. Neuropilin 2 and soluble neuropilin 2 in neuroendocrine neoplasms.
Gerard L; Patte C; Chardon L; Hervieu V; Payen L; Allio M; Marx C; Clermidy H; Durand A; Mehlen P; Bollard J; Poncet G; Roche C; Gibert B; Walter T
Endocr Relat Cancer; 2024 Jun; 31(6):. PubMed ID: 38642579
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Threshold for Circulating Tumor Cells in Patients With Pancreatic and Midgut Neuroendocrine Tumors.
Mandair D; Khan MS; Lopes A; Furtado O'Mahony L; Ensell L; Lowe H; Hartley JA; Toumpanakis C; Caplin M; Meyer T
J Clin Endocrinol Metab; 2021 Mar; 106(3):872-882. PubMed ID: 33180939
[TBL] [Abstract][Full Text] [Related]
5. Circulating Tumour Cells in the Prediction of Bone Metastasis.
Choi SW; Sun AK; Cheung JP; Ho JC
Cancers (Basel); 2024 Jan; 16(2):. PubMed ID: 38254743
[TBL] [Abstract][Full Text] [Related]
6. The Quest for Circulating Biomarkers in Neuroendocrine Neoplasms: a Clinical Perspective.
Mariën L; Islam O; Chhajlani S; Lybaert W; Peeters M; Van Camp G; Op de Beeck K; Vandamme T
Curr Treat Options Oncol; 2023 Dec; 24(12):1833-1851. PubMed ID: 37989978
[TBL] [Abstract][Full Text] [Related]
7. Role of Selected Circulating Tumor Biomarkers in Patients with Skeletal Metastatic Pancreatic Neuroendocrine Neoplasms.
Rosiek V; Janas K; Witkowska M; Kos-Kudła B
J Clin Med; 2023 Jul; 12(14):. PubMed ID: 37510802
[TBL] [Abstract][Full Text] [Related]
8. Circulating biomarkers for diagnosis and therapeutic monitoring in bone metastasis.
Song MK; Park SI; Cho SW
J Bone Miner Metab; 2023 May; 41(3):337-344. PubMed ID: 36729305
[TBL] [Abstract][Full Text] [Related]
9. Risk Stratification of Pancreatic Neuroendocrine Neoplasms Based on Clinical, Pathological, and Molecular Characteristics.
Choi JH; Paik WH
J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36556070
[TBL] [Abstract][Full Text] [Related]
10. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies.
Lee L; Ramos-Alvarez I; Jensen RT
Cancers (Basel); 2022 Feb; 14(5):. PubMed ID: 35267558
[No Abstract] [Full Text] [Related]
11. Current and New Challenges in the Management of Pancreatic Neuroendocrine Tumors: The Role of miRNA-Based Approaches as New Reliable Biomarkers.
Havasi A; Sur D; Cainap SS; Lungulescu CV; Gavrilas LI; Cainap C; Vlad C; Balacescu O
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163032
[TBL] [Abstract][Full Text] [Related]
12. Predicting Bone Metastasis Using Gene Expression-Based Machine Learning Models.
Albaradei S; Uludag M; Thafar MA; Gojobori T; Essack M; Gao X
Front Genet; 2021; 12():771092. PubMed ID: 34858485
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine neoplasia and bone (Review).
Ghemigian A; Carsote M; Sandru F; Petca RC; Oproiu AM; Petca A; Valea A
Exp Ther Med; 2021 Nov; 22(5):1219. PubMed ID: 34584564
[TBL] [Abstract][Full Text] [Related]
14. The Potential Role of Liquid Biopsies in Advancing the Understanding of Neuroendocrine Neoplasms.
Shah D; Lamarca A; Valle JW; McNamara MG
J Clin Med; 2021 Jan; 10(3):. PubMed ID: 33494364
[TBL] [Abstract][Full Text] [Related]
15. Dual-Targeted Extracellular Vesicles to Facilitate Combined Therapies for Neuroendocrine Cancer Treatment.
Si Y; Guan J; Xu Y; Chen K; Kim S; Zhou L; Jaskula-Sztul R; Liu XM
Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33187322
[TBL] [Abstract][Full Text] [Related]
16. Current and Emerging Biomarkers Predicting Bone Metastasis Development.
Iuliani M; Simonetti S; Ribelli G; Napolitano A; Pantano F; Vincenzi B; Tonini G; Santini D
Front Oncol; 2020; 10():789. PubMed ID: 32582538
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review.
Bocchini M; Nicolini F; Severi S; Bongiovanni A; Ibrahim T; Simonetti G; Grassi I; Mazza M
Front Oncol; 2020; 10():831. PubMed ID: 32537434
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.
Lee L; Ito T; Jensen RT
Expert Rev Anticancer Ther; 2019 Dec; 19(12):1029-1050. PubMed ID: 31738624
[No Abstract] [Full Text] [Related]
19. Bone Metastases in Neuroendocrine Neoplasms: From Pathogenesis to Clinical Management.
Altieri B; Di Dato C; Martini C; Sciammarella C; Di Sarno A; Colao A; Faggiano A;
Cancers (Basel); 2019 Sep; 11(9):. PubMed ID: 31500357
[TBL] [Abstract][Full Text] [Related]
20. Clinical applications of (epi)genetics in gastroenteropancreatic neuroendocrine neoplasms: Moving towards liquid biopsies.
Boons G; Vandamme T; Peeters M; Van Camp G; Op de Beeck K
Rev Endocr Metab Disord; 2019 Sep; 20(3):333-351. PubMed ID: 31368038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
